Company profileNeural interface
Coherence Neuro
A neural interface aimed at brain cancer: record from and stimulate the cortex around a tumour.
- Location
- San Francisco, United States
- Class
- Neural interfaceA thin-film cortical probe that records and stimulates, in first human use during surgery. Its stated purpose is monitoring and treating brain cancer, not decoding intent.Not counted among core BCI companies.
- Also known as
- Coherence Neuro Global · Coherence Neuro Australia Pty Limited · Coherence Neuro Australia
- Website
- coherenceneuro.com
- Sources last checked
- 6 Oct 2026
What they are building
San Francisco startup. Its CIPHER system is a flexible, electrode-dense thin-film probe for the cortical surface that records and stimulates. Its first use in people is during glioma surgery at the Royal Melbourne Hospital, sponsored by its Australian subsidiary.
- Interface category
- Electrocorticography · ECoG, recording and stimulating
- Signal
- ECoG: Local field potentials, including high-gamma activityECoG + stim: Field potentials out; electrical pulses in
- Invasiveness
- Invasive
- Recording / stimulation
- Recording and stimulation
- Main use cases
- Monitor, Restore
- Works with
- Royal Melbourne Hospital
Where they are clinically
First-in-human
The first use of a device in a small number of people, focused on safety.
The first-in-human study uses the probe for short periods during tumour surgery, to assess safety, handling and basic performance. It is not a chronic implant.
Access today
Experimental human research
Demonstrated in a small number of research participants. Not an established treatment.
- Shown in people
- First use in people has begun: short recording and stimulation during tumour surgery. No data are public.
- Still an aim
- An implant that monitors and modulates brain cancer continuously, which is the company's stated vision.
- What stands in the way
- The premise: that tumour-related activity can be read from the cortex, and that stimulating in response helps.
On record here: 0 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
Why this company matters
Coherence Neuro points neural-interface hardware at a disease the field has not addressed. Its aim is an implant that reads the activity around a tumour and stimulates in response. The first step is the one other thin-film makers took: short use in an operating theatre. Everything beyond that, including whether tumour-related activity can be read and usefully acted on, is a hypothesis.
Key milestones
23 Jun 2026
Company announces the start of the study at the Royal Melbourne Hospital.
22 May 2026
First-in-human study of CIPHER during glioma surgery begins recruiting in Melbourne; ten participants planned.
Competitive context
ECoGApproved / cleared
Precision Neuroscience
A thin-film cortical surface array that slides under the skull through a narrow slit.
ECoGFirst-in-human
INBRAIN Neuroelectronics
Graphene-based cortical interfaces for high-resolution recording and stimulation.
ECoGFirst-in-human
Neurosoft Bioelectronics
Soft, stretchable electrode arrays for the brain surface, tested during surgery in people.
Sources
- 01
Coherence Neuro has started its first clinical study (opens in a new tab)
Company reportedCoherence Neuro23 Jun 2026Checked against source 6 Oct 2026
Describes the company as San Francisco-based, the probe as a flexible thin film that records and stimulates, and the study as short intraoperative use at the Royal Melbourne Hospital.
- 02
Clinical registryClinicalTrials.govChecked against source 5 Oct 2026
Sponsor Coherence Neuro Australia Pty Limited. Recruiting since 22 May 2026 in Melbourne; 10 participants planned.